Aquestive Therapeutics (NASDAQ:AQST) Stock: Insider Richard Daly Buys 28,025 Shares

Key Points

• Director Richard Daly purchased 28,025 Aquestive Therapeutics shares at an average price of $3.54, investing about $99,209; the purchase was disclosed in an SEC filing.
• Aquestive reported quarterly EPS of -$0.13, missing the consensus estimate of -$0.12, and revenue of $7.56 million, below analyst estimates of $11.02 million.
• Analysts’ average rating is “Moderate Buy,” with an average price target of $8.75; individual targets cited ranged from $10 to $11, alongside some sell ratings.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) Director Richard Daly bought 28,025 shares of the company's stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average cost of $3.54 per share, with a total value of $99,208.50. Following the acquisition, the director directly owned 28,025 shares in the company, valued at $99,208.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Aquestive Therapeutics Stock Down 0.4%

AQST stock traded down $0.01 during trading on Thursday, reaching $3.56. The company's stock had a trading volume of 1,599,653 shares, compared to its average volume of 2,924,075. The company's fifty day moving average is $4.44 and its 200-day moving average is $4.21. The company has a market capitalization of $448.08 million, a P/E ratio of -5.57 and a beta of 1.49. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $6.74.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $7.56 million during the quarter, compared to analyst estimates of $11.02 million. Analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds have recently bought and sold shares of AQST. China Universal Asset Management Co. Ltd. lifted its position in Aquestive Therapeutics by 14.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,901 shares of the company's stock valued at $107,000 after purchasing an additional 2,936 shares during the last quarter. International Assets Investment Management LLC increased its holdings in shares of Aquestive Therapeutics by 27.0% in the 1st quarter. International Assets Investment Management LLC now owns 22,895 shares of the company's stock worth $95,000 after buying an additional 4,870 shares during the last quarter. Quantinno Capital Management LP increased its holdings in shares of Aquestive Therapeutics by 52.8% in the 1st quarter. Quantinno Capital Management LP now owns 18,014 shares of the company's stock worth $75,000 after buying an additional 6,221 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at about $30,000. Finally, Engineers Gate Manager LP raised its position in shares of Aquestive Therapeutics by 20.5% during the 2nd quarter. Engineers Gate Manager LP now owns 49,879 shares of the company's stock valued at $207,000 after buying an additional 8,496 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AQST shares. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a report on Friday, October 16th. Cantor Fitzgerald restated an "overweight" rating and set a $11.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen downgraded shares of Aquestive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, November 7th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $8.75.

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company's products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.